The Winter 2024 CMTA Report is a CMTA-STAR special edition that captures a year of bold progress in CMT. The issue showcases CMTA-STAR’s remarkable progress in developing gene therapies for CMT1A and CMT4C and clinical trials like the Phase III INSPIRE trial for CMT-SORD. This special edition also highlights the CMTA-INC Strategic Alliance, a global partnership advancing research and patient care. Stories of community impact, such as the Paulsen family’s dedication to CMT4C research, demonstrate the power of collective action. Together, these achievements underline CMTA’s unwavering commitment to deliver help for today and hope for tomorrow for everyone affected by CMT.
Read the full stories and more in the Winter 2024 CMTA Report.